Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences’ Frontiers in Cancer Immunotherapy Symposium

▤ Summary

Anixa Biosciences announced that it will present two clinical-stage immunotherapy programs at a cancer immunotherapy symposium in New York. One presentation covers its ovarian cancer CAR-T therapy, lira-cel, and will share ongoing Phase 1 trial status and positive survival observations. The other presentation covers its breast cancer vaccine and will share final Phase 1 results showing that major primary endpoints were met and immune responses appeared in 74% of participants. The company also highlighted its collaborations with research institutions such as Moffitt Cancer Center and Cleveland Clinic.

▦ Linked Companies